dalteparin has been researched along with ST Elevated Myocardial Infarction in 10 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS)." | 8.95 | Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis. ( Bundhun, PK; Shaik, M; Yuan, J, 2017) |
| "Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS)." | 4.95 | Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis. ( Bundhun, PK; Shaik, M; Yuan, J, 2017) |
| "Risk of bleeding was assessed with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) scale, and risk of major bleeding in patients with NSTEMI was additionally assessed with the CRUSADE scale." | 1.72 | Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM. ( Boytsov, SA; Erlikh, AD; Gulyan, RG; Pevsner, DV; Shakhnovich, RM; Tereschenko, SN, 2022) |
| " The secondary endpoints were a composite of major adverse cardiovascular events (MACE) consisting of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, a new target vessel revascularisation and all-cause mortality at 30 days." | 1.43 | Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction. ( Laine, M; Nieminen, T; Tierala, I; Viikilä, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boytsov, SA | 3 |
| Shakhnovich, RM | 3 |
| Tereschenko, SN | 3 |
| Erlikh, AD | 3 |
| Pevsner, DV | 3 |
| Gulyan, RG | 3 |
| Singh, N | 1 |
| Singh Lubana, S | 1 |
| Tsai, HM | 1 |
| Yan, Y | 2 |
| Wang, X | 1 |
| Guo, J | 1 |
| Li, Y | 1 |
| Ai, H | 1 |
| Gong, W | 1 |
| Que, B | 1 |
| Zhen, L | 1 |
| Lu, J | 1 |
| Ma, C | 1 |
| Montalescot, G | 2 |
| Nie, S | 1 |
| Bundhun, PK | 1 |
| Shaik, M | 1 |
| Yuan, J | 1 |
| Shavadia, J | 1 |
| Welsh, R | 1 |
| Gershlick, A | 1 |
| Zheng, Y | 1 |
| Huber, K | 1 |
| Halvorsen, S | 1 |
| Steg, PG | 1 |
| Van de Werf, F | 1 |
| Armstrong, PW | 1 |
| Silvain, J | 1 |
| O'Connor, SA | 1 |
| Kerneis, M | 1 |
| Hauguel-Moreau, M | 1 |
| Zeitouni, M | 1 |
| Overtchouk, P | 1 |
| Ankri, A | 1 |
| Brugier, D | 1 |
| Vicaut, E | 1 |
| Ecollan, P | 1 |
| Galier, S | 1 |
| Collet, JP | 1 |
| Viikilä, J | 1 |
| Nieminen, T | 1 |
| Tierala, I | 1 |
| Laine, M | 1 |
| Ghaffarian, K | 1 |
| Furin, M | 1 |
| Bassett, R | 1 |
| Auffret, V | 1 |
| Leurent, G | 1 |
| Boulmier, D | 1 |
| Bedossa, M | 1 |
| Zabalawi, A | 1 |
| Hacot, JP | 1 |
| Coudert, I | 1 |
| Filippi, E | 1 |
| Castellant, P | 1 |
| Rialan, A | 1 |
| Rouault, G | 1 |
| Druelles, P | 1 |
| Boulanger, B | 1 |
| Treuil, J | 1 |
| Avez, B | 1 |
| Le Guellec, M | 1 |
| Gilard, M | 1 |
| Le Breton, H | 1 |
| White, HD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Comparison of Anticoagulation After Primary Percutaneous Coronary Intervention Using Enoxaparin, ACT Guided Unfractionated Heparin or Bivalirudin Prolongation vs. no Anticoagulation To Improve Clinical Outcome[NCT03664180] | Phase 4 | 2,989 participants (Actual) | Interventional | 2019-01-11 | Completed | ||
| STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623] | Phase 3 | 1,899 participants (Actual) | Interventional | 2008-03-01 | Completed | ||
| Acute STEMI Treated With Primary Angioplasty and Intravenous 0.5 mg/kg Lovenox or UFH to Lower Ischemic and Bleeding Events[NCT00718471] | Phase 3 | 910 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 50 |
| Primary PCI (Group B) | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 59 |
| Primary PCI (Group B) | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 100 |
| Primary PCI (Group B) | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 117 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 77 |
| Primary PCI (Group B) | 85 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 43 |
| Primary PCI (Group B) | 42 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 116 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 31 |
| Primary PCI (Group B) | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 41 |
| Primary PCI (Group B) | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 57 |
| Primary PCI (Group B) | 72 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 9 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 6 |
| Primary PCI (Group B) | 3 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 61 |
| Primary PCI (Group B) | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 206 |
| Primary PCI (Group B) | 191 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 23 |
| Primary PCI (Group B) | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 45 |
| Primary PCI (Group B) | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 19 |
| Primary PCI (Group B) | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 1 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 32 |
| Primary PCI (Group B) | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 10 |
| Primary PCI (Group B) | 29 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 2 |
| Primary PCI (Group B) | 0 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 7 |
| Primary PCI (Group B) | 4 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 8 |
| Primary PCI (Group B) | 1 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 267 |
| Primary PCI (Group B) | 236 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 15 |
| Primary PCI (Group B) | 5 |
1 review available for dalteparin and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Chi-Square Distribution; Enoxaparin; Female; Fondapar | 2017 |
2 trials available for dalteparin and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infar
Topics: Anticoagulants; Double-Blind Method; Enoxaparin; Heparin; Hirudins; Humans; Multicenter Studies as T | 2020 |
Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin.
Topics: Aged; Anticoagulants; Antithrombin III; Biomarkers; CD40 Ligand; Enoxaparin; Factor Xa; Female; Hepa | 2018 |
7 other studies available for dalteparin and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia.
Topics: Aged; Antithrombins; Arginine; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Pipecolic Acids; Py | 2020 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F | 2016 |
Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction.
Topics: Aged; Antithrombins; Cause of Death; Dose-Response Relationship, Drug; Drug Therapy, Combination; El | 2016 |
STEMI in a young female? Consider spontaneous peripartum coronary artery dissection.
Topics: Adult; Anticoagulants; Coronary Angiography; Coronary Vessel Anomalies; Diagnosis, Differential; Eno | 2017 |
Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
Topics: Anticoagulants; Antithrombins; Electrocardiography; Enoxaparin; Female; Follow-Up Studies; Heparin; | 2016 |
Adjunctive antithrombotic therapy with primary percutaneous coronary intervention in ST elevation myocardial infarction: ATOLL in perspective.
Topics: Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Percutaneous Coronary Intervention; ST Elevation M | 2019 |